HUTCHMED (China) Limited American Depositary Shares
HCMStock
$11.61
Market Cap$15.89B
P/E4.43x
Div yield—
Beta1.20
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.15%
Price vs S&P 500 (4W)9.43%
VGM Score48.60
Market Capitalization$15.89B
P/E Ratio (Annual)4.43x
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.22
4.22
4.27
4.27
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HCMHUTCHMED (China) Limited American Depositary Shares | C | C | C | $11.61 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
HUTCHMED is a biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases. The company maintains a robust pipeline of cancer drug candidates in clinical development while leveraging significant commercial infrastructure in China. Operating across Oncology/Immunology and Other Ventures segments, HUTCHMED combines early-stage innovation with established regional market presence.